Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer


Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110

Abstract

Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread.

Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice.

Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.

Keywords

myeloid-derived suppressor cells; pancreatic cancer; immune suppression; bone marrow; metastasis

INTRODUCTION

Pancreatic adenocarcinoma: prognosis and clinical management

Pancreatic adenocarcinoma, referred to further in this review as pancreatic cancer, is a highly aggressive malignancy and the fourth leading cause of cancer deaths in the United States with over 43,000 estimated new cases in 2010 [1]. The prognosis of these patients is dismal with overall survival less than 2% and a median survival of 4 to 6 months. The
significance of this malignancy is further illustrated by comparing the estimated 36,800 deaths from pancreatic cancer in 2010 to the estimated 32,050 and 40,230 deaths from prostate and breast cancer, respectively [1]. The poor prognosis of pancreatic cancer is related to a combination of late detection and ineffective treatment regimens. Surgical resection is the only known curative treatment for pancreatic cancer, however, only 15-20% of patients present with operable disease [2]. Among these patients median survival is 15-20 months with approximately 20% five-year survival rate [3, 4].

The current Federal Drug Administration-approved therapy for unresectable pancreatic cancer is gemcitabine monotherapy based on a Phase III clinical trial from 1997 demonstrating a median survival of 5.5 months and 18% 1-year survival [5]. Although gemcitabine-based chemotherapeutic regimens are considered to be first line treatments, pancreatic cancer is notoriously chemo-resistant and effectiveness of chemotherapeutics remains disappointing. Multiple combinations of chemotherapeutic drugs as well as combinations of chemotherapy and biological agents have been explored [6] in the interest of improving on this limitedly effective therapy in both non-surgical and surgical patients. Recently, the combination of erlotinib plus gemcitabine was shown to improve 1-year overall survival and median survival among patients with advanced pancreatic cancer but the overall benefit was modest at the cost of increased toxicity [7].

Investigators at the Virginia Mason Clinic in Seattle recently reported the results of their Phase II trial using an interferon-alpha (IFNα) based chemoradiation regimen in patients after resection in which the 2-year overall survival reached 64% [8]. We concluded a similar Phase II trial utilizing adjuvant IFN-α, gemcitabine, 5-FU, and radiation and demonstrated a similar 2-year overall survival of 56% [9]. This compares favorably to the outcomes of a variety of randomized clinical trials using radiation and chemotherapy following surgery [10-12]. More recently, novel neo-adjuvant gemcitabine-based chemoradiation protocols have been introduced with encouraging results [13, 14]. Given the above results using adjuvant immunomodulatory strategies and neo-adjuvant chemoradiation, combining the two is a logical next step. It is important to note that while gemcitabine blocks DNA synthesis resulting in inhibition of tumor replication and lysis of tumor cells [15], data from animal studies shows evidence that gemcitabine selectively depletes myeloid derived suppressor cells (MDSC) and improves T cell immune responses, raising the possibility of an immunologic component to gemcitabine monotherapy [16, 17].

THE IMMUNE RESPONSE TO PANCREATIC CANCER

Human tumors of non-hematopoietic origin are generally characterized by infiltrating leukocytes. The presence of an immune cell infiltrate has been interpreted as the host's response to the developing tumor. Indeed, in several types of malignancies the extent of immune infiltrate correlates with good prognosis [18, 19]. A detailed analysis of the tumor infiltrate in colorectal carcinomas implicated cell type, density, and location as prognostic indicators [20, 21]. However, equally convincing and numerous are reports describing a worse prognosis with increasing intensity of infiltrate [20, 22]. Key in the discrepancy of these findings may be the composition of the immune infiltrate; a recent study suggests that the presence of a lymphocytic infiltrate, in particular the presence of memory Th1 and cytotoxic T cells (CTL) are strong prognostic factors for long term survival (Figure 1) [19]. The presence of immune suppressor cells such as T regulatory cells (Treg) and myeloid-derived suppressor cells (MDSC) on the other hand may worsen prognosis.

Progress in basic and translational immunology has confirmed the importance of the immune system in cancer prevention and prognosis, and has renewed interest in vaccine therapy for cancer [19, 20, 23]. A number of proteins overexpressed by most pancreatic...
cancers have been explored as targets for immune-based therapies such as mucin-1, carcinoembryonic antigen, K-RAS, and mesothelin [24]. While it has been observed that patients with advanced pancreatic cancer exhibit depressed immuno-responsiveness [25, 26] and therefore may not be appropriate candidates for immunotherapy, several clinical studies [25, 27, 28] have demonstrated this patient population can effectively mount immune responses to vaccines. There is strong evidence for the presence of circulating tumor-specific immune effector cells in patients with pancreatic cancer [29-31] that can be expanded by active immunization [24, 27, 32]. Studies from our group have focussed on mesothelin as a immunologic target in pancreatic cancer. Mesothelin is a ubiquitous antigen that is nearly universally expressed by pancreatic adenocarcinoma which is the most common histologic type of pancreas cancers composing about 85% of all tumors [33, 34]. In vitro stimulation with purified mesothelin protein induced mesothelin-specific reactivity in both CD4 and CD8 T cells from patients with diverse MHC backgrounds [35], further confirming that patients with pancreatic cancer contain tumor-specific T cells that can be expanded and potentially exploited therapeutically.

In spite of these encouraging findings, significant clinical responses are rare [24, 25, 27], illustrating one of the major limitations immune-based therapies face: the induction of specific antitumor immune effector cells in peripheral blood does not necessarily translate into durable antitumor immune responses. It is interesting to note that two components of the immune suppressor network are independent predictors of prognosis in pancreatic cancer. Both the prevalence of Treg [36, 37] and expression levels of Programmed Death-1 ligand (PD-L1), a key immune regulatory molecule have prognostic value [38]. Treg suppress immune effector cells through a variety of mechanisms (discussed below), whereas PD-L1 induces cell death in PD-1-expressing cells such as activated T cells [39]. The finding that both Treg and PD-L1 are prognostic factors further argues that pancreatic cancer induces an immune response that, when harnessed appropriately, might have an impact on clinical responses.

Immune suppression in pancreatic cancer

Over the past several years, a number of reviews have described mechanisms of immune evasion [40, 41]. Although specific information on immune escape mechanisms in pancreatic cancers is limited, recent findings suggest that tumor-induced mechanisms of immune suppression are the main reason for the weak clinical responses to immune-based therapies [42-44]. Immune suppression is mediated by both soluble factors such as TGFβ, prostaglandins, and IL-10 [44], and suppressor cells such as MDSC and Treg. In addition to directly inhibiting antitumor immunity, soluble tumor-derived factors promote the generation of immune suppressor cells which can alter the immune balance and thus the type of predominant immune response. For example, reduced levels of IL-2 and increased levels of IL-10 promote differentiation of CD4+ Th2 cells over Th1 cells thereby limiting cellular antitumor immunity [26]. Cytokines in the tumor environment have also been shown to induce expression of the tryptophan degrading enzyme indoleamine 2, 3-dioxygenase (IDO) in macrophages and dendritic cells. As tryptophan is necessary for effective T cell activation, depletion of tryptophan by IDO results in T cell suppression [45]. Similarly, tumor-derived factors interfere with normal bone marrow myelopoiesis, promoting the formation of MDSC and inhibiting normal differentiation of antigen-presenting dendritic cells. Treg and, more recently, MDSC have been associated with immune suppression and tumor promotion (Figure 1) [46, 47].
Bone marrow-derived immune suppressor cells have been described in tumor-bearing mice since the late 1970s [48, 49]. These cells are of myeloid origin and were initially characterized as suppressor macrophages [48-51]. It was not until the 1990s that investigators focused more intensely on these cells in cancer patients [52-54]. Although initially termed “myeloid suppressor cells” or “immature myeloid cells” they have more accurately been renamed “myeloid-derived suppressor cells”, or MDSC to better reflect the origin and function of these undifferentiated myeloid cells [55]. MDSC comprise heterogeneous populations of immature cells arising from the myeloid lineage that share common functional and phenotypical characteristics. They are observed with increased prevalence in the peripheral blood and in the tumor microenvironment of patients with solid tumors [56], including pancreatic cancer [52, 57-60]. MDSC are also increased in many pathologic conditions such as infections, inflammatory diseases, sepsis, and traumatic shock, and serve to down regulate T cell responses. While MDSC were initially pursued because of their suppressive effect on antitumor immunity, investigators have learned that they may have a direct impact on cancer biology independent of the immune system such as by promoting tumor growth and formation of metastases.

**MDSC origin and phenotype**

MDSC are bone marrow-derived cells of myeloid origin that are present in blood, lymph nodes, spleen, tumors, and immune-activated tissues. The production of these cells results from an altered hematopoietic differentiation pathway leading to the expansion and accumulation of a heterogenous population of immature myeloid cells. Hematopoiesis is typically represented as a hierarchical process (Figure 2). Normal developmental hematopoietic pathways have largely been defined based on expression of surface and intracellular markers. The hematopoietic stem cell is the most important, which in addition to self-renewal can initiate hematopoiesis which gives rise to all blood cells [61]. The hematopoietic stem cell can differentiate into hematopoietic progenitor cells that give rise to multipotential progenitor cells (Figure 2). In turn these cells give rise to myeloid and lymphoid progenitor cells.

The myeloid progenitor cells further differentiate into immature myeloid cells. It is at this stage that the cells can leave the bone marrow and enter the peripheral circulation. Normally, the myeloid cells will migrate to various peripheral organs where they undergo differentiation into mature myeloid cells such as macrophages, dendritic cells, or granulocytes. However, under conditions such as infections, sepsis/trauma [62, 63], or in a tumor environment [64], the differentiation of immature myeloid cells into normal mature myeloid cells is blocked, and at the same time the immature myeloid cells are activated and become MDSC (Figure 2).

Additionally, altered differentiation of immature myeloid cells has been noted, for example in a tumor environment. Instead of giving rise to mature macrophages, some immature myeloid cells differentiate into tumor-associated macrophages (TAM) that are functionally and phenotypically distinct from normal mature macrophages [65-67]. Based on expression of differentiation markers, TAM, tumor-infiltrating dendritic cells [68] and mast cells differ from MDSC [65, 66, 69-71], but caution should be taken with classification of myeloid cells into various cell types, as the distinction between “immature” and “alternatively differentiated” may not always be clear.
The diverse heterogeneity of MDSC has made characterization difficult [72]. In humans, MDSC express CD11b (common myeloid marker, alpha M-integrin, Mac-1) and myelomonocytic/macrophage markers such as CD14 and CD33 (common myeloid marker), or granulocyte/neutrophil markers including CD15 (neutrophil marker, Lewis X antigen), often without exhibiting markers of terminal differentiation (Lin<sup>−</sup>Dr<sup>lo</sup>) [73-75]. Recent studies on MDSC in cancer patients have shown that at least two subsets of human MDSC exist: CD11b<sup>+</sup>CD33<sup>+</sup> cells that are CD15<sup>+</sup> [57, 59, 60] or CD66b<sup>+</sup> [58, 76], and CD15<sup>−</sup>CD14<sup>+</sup>DR<sup>lo</sup> cells [77-80]. The prevalence of each subset appears disease-related, as the CD15<sup>+</sup> cells were detected in patients with renal cell carcinoma [57], non-small cell lung cancer [60] and pancreatic adenocarcinoma [59], whereas monocytic MDSC (CD14<sup>+</sup>) were detected in patients with glioblastoma [81], ovarian carcinoma [82], hepatocellular carcinoma [77], malignant melanoma [78, 79, 83], bladder, and prostate cancer [84, 85].

Our preliminary data show that the tumor microenvironment in pancreatic adenocarcinoma contains both monocytic MDSC (CD11b<sup>+</sup>CD14<sup>+</sup>) and granulocytic MDSC (CD11b<sup>+</sup>CD15<sup>+</sup>) (Figure 3). There is also a subset that expresses both CD14 and CD15, confirming the immature phenotype of MDSC. In contrast, no MDSC infiltrate was detected in normal pancreas tissue (not shown). In the periphery, the CD11b<sup>+</sup> subset co-expressing CD15 is significantly greater in patients compared to age-matched controls. Patients with advanced pancreatic cancer also have a significantly expanded CD11b<sup>+</sup> subset that co-expresses CD14 instead of CD15, as determined by flow cytometry (unpublished observations).

The monocytic and granulocytic human MDSC subsets resemble those identified in murine tumors [86, 87]. In mice, MDSC are characterized by co-expression of CD11b and Gr-1 [64, 72, 75, 88, 89], a granulocyte marker also known as Ly6G (Figure 2). Some MDSC express high levels of Gr-1 and display a granulocytic morphology whereas other MDSC expressing low levels of Gr-1 resemble monocytes [65], and highly express Ly6C [87]. It has been observed that due to hypoxia monocytic MDSC rapidly differentiate into TAM in the tumor environment[90], expressing F4/80 (mouse) [71, 86, 91] or CD68 (human), hence the phenotypic and functional overlap between tumor-derived MDSC and TAM [67, 70, 92]. Other MDSC markers that have been reported are CD115 (M-CSF or GSF-1 receptor) [93] and CD124, the IL-4 receptor α (IL-4Rα) [65, 71, 86]. It should be noted, however, that unlike CD11b and Gr-1, CD115 and CD124 may not be involved with immunosuppressive MDSC in all tumor models [46].

**MDSC actively suppress host immunity**

MDSC from tumor-bearing hosts directly suppress antigen-specific T cell-mediated immunity [94]. This became evident when investigators explored why patients with advanced cancers responded so poorly to various vaccination protocols: poor responses were associated with an increased prevalence of immature myeloid cells and a decrease in dendritic cells. Increased numbers of MDSC in the tumor and peripheral blood were initially noted in patients with head and neck cancer [52, 95, 96], and their increased prevalence was confirmed in patients with other cancers [46, 97, 98]. Initial studies focused on CD34<sup>+</sup> myeloid cells that are precursors of granulocytes and/or antigen presenting macrophages and dendritic cells. While the CD34<sup>+</sup> cells could be induced to differentiate into functionally active dendritic cells in vitro, freshly isolated CD34<sup>+</sup> cells from cancer patients inhibited IL-2 production by anti-CD3 antibody-stimulated intratumoral T cells. Likewise, in vitro depletion of CD15<sup>+</sup> cells [57, 99] or CD66b<sup>+</sup> cells [58] restored IFNγ secretion, T cell proliferation and TCR expression in anti-CD3-activated peripheral blood lymphocytes from patients with advanced renal cell carcinoma. Suppression of T cell function is not restricted to non-specific T cell activation, as shown by Kusmartsev et al. using CD33<sup>+</sup>DR<sup>+</sup> MDSC from metastatic renal cancer patients that inhibited antigen-specific T cell IFN-γ secretion and cytolytic activity [100]. In patients with metastatic pancreatic or colon cancer, dramatic
accumulation of CD15+ low-density granulocytes actively suppressed TCR expression and cytokine production [59].

There is ample evidence in experimental tumor models that MDSC perturb antitumor immunity [91]. Mouse MDSC suppress both antigen-specific and non-specific T cell responses, but suppression is limited to the site where MDSC are exposed to stimuli [101]. This may depend on the compartment from which they are derived: tumor-derived MDSC suppress both antigen-specific and non-specific T cell responses whereas spleen-derived MDSC suppressed non-specific T responses only [46]. While this may be a reflection of how the tumor microenvironment influences MDSC, it is also possible that the subset composition of MDSC differs in various compartments. For example, recognizing that Gr-1+ cells comprise both Ly6G (Gr-1high) and Ly6C (Gr-1low) cells [87], it is possible that each subset employs its own unique migratory and functional characteristics. Further evidence for MDSC-mediated T cell suppression comes from studies in which MDSC were specifically targeted: reduction of MDSC prevalence restores T and NK cell activity, and promotes tumor immune surveillance and the host response to cancer vaccines [46, 97]. Lastly, the importance of MDSC in controlling antitumor immunity is also highlighted in aging mice that are at increased risk of developing tumors. Aging is associated with an increased prevalence of MDSC which may contribute to the increased incidence of tumor [102].

The regulation of innate immunity by MDSC is more controversial. Several studies demonstrated MDSC-mediated inhibition of NK antitumor cytotoxicity and IFNγ release [103], but another study showed MDSC activated NK cells through expression of Rae-1, a ligand for the activation receptor NKG2D on NK cells [104]. Further characterization of MDSC subsets may clarify this discrepancy.

MDSC also interact with NKT cells. While NKT cells comprise only a small subset of immune cells, they have profound effects on other immune subsets [105]. The type II NKT cells that are characterized by a variable T cell receptor facilitate MDSC recruitment and tumor growth through secretion of IL-13 [106] which can bind to the IL-4Rα on MDSC and activate MDSC [65, 105]. In contrast, type I NKT cells or invariant NKT cells produce IFNγ and thereby promote macrophage-mediated antitumor activity [105].

In addition to the direct suppression of immune effectors, MDSC can skew the immune repertoire from anti-tumor to pro-tumor, for example by promoting CD4 Th2 rather than Th1 cells [107], or by promoting the recruitment and expansion of suppressor Treg [93, 108].

**MDSC promote Treg**

MDSC have been implicated in the recruitment and maintenance of Treg [93, 98, 109, 110]. It has been shown that immature dendritic cells preferentially stimulate Treg [111]. Essential for the stimulation of Treg is the tumor-induced ability of the dendritic cells to produce TGFβ [112]. Treg, in turn, have been identified as master regulators of immune homeostasis by maintaining peripheral tolerance to self-antigens through suppression of self-reactive T cells [113-116]. As most tumor antigens are self-antigens, Treg also suppress antitumor immunity [117-119]. Elevated levels of Treg have been observed in many histologically-different types of cancer [117, 120] which has been shown in several of these to correlate with decreased survival [37, 121, 122]. The interplay between MDSC and Treg creates a powerful barrier against immune attack.

**MDSC immune suppressor mechanisms**

MDSC use a variety of mechanisms to control antitumor immunity mediated by secreted molecules and/or expression of particular cell surface molecules (Table 1). Most of these...
mechanisms have been identified in experimental models and await validation in cancer patients. One such mechanism is the release of reactive oxygen species (ROS) [59, 96, 123] and peroxynitrite that catalyze nitration of the TCR and thereby prevent interaction of the TCR with peptide-MHC complexes [124, 125]. A second, well-documented mechanism is the depletion of arginine from the environment [57, 58, 126]. L-arginine is an amino acid essential for T cell replication and production of the TCR signaling molecule, zeta. MDSC express high levels of arginase 1 and inducible nitric oxide synthase (iNOS), two enzymes that degrade arginine and the TCRζ chain, and thereby block T cell activation and proliferation [60, 87]. Arginase 1 converts arginine into ornithine and urea, whereas iNOS converts arginine into nitric oxide (NO) which can suppress T cell activation and induce apoptosis [127-129]. The finding that both arginase 1 and iNOS are activated in MDSC is further evidence that MDSC do not fit the strict separation into classically or alternatively activated macrophages [130]. T cell function can be restored by using specific arginase 1 or iNOS inhibitors. Similarly, MDSC can deprive the environment of cysteine, another amino acid that is essential for T cell activation [97, 131, 132]. MDSC are dependent on cysteine as well, and import cystine for conversion into cysteine. T cells lack the ability to import cysteine, and are dependent on cysteine which is normally produced by mature dendritic cells and macrophages during antigen presentation [131]. Additional mechanisms of suppression include the recently described down-regulation of the lymph node homing receptor, CD62L on CD4 and CD8 T cells [132, 133]. Down regulation of CD62L results in lack of T cell activation, as T cells do not migrate to lymph nodes where they would otherwise be activated.

Other suppressor mechanisms are related to the secretion of cytokines by activated MDSC. For example, MDSC can be activated by TAM to increase production of IL-10 which in turn down-regulates IL-12 secretion by macrophages [107]. Another immunosuppressive cytokine produced by MDSC is TGFβ which can block CTL activity. TGFβ has also been implicated in activation and expansion of Treg, although TGFβ-independent induction of Treg by MDSC has been described recently. In the latter case, expression of CTLA-4 (CD152) was required on MDSC. Other T cell inhibitory molecules may be expressed on MDSC such as B7-H4 [134] and PD-L1 (B7-H1) [135, 136] that when crosslinked to their respective receptors on activated T cells induce down-regulation.

MDSC promote tumor angiogenesis and metastasis

In addition to immune suppression, MDSC may directly promote tumor development by inducing angiogenesis [137, 138] and formation of distant metastasis [139-142]. Through secretion of factors that induce bone marrow mobilization such as VEGF and G-CSF, tumors activate myeloid precursors in the bone marrow [143]. The mobilization is associated with changes in the mechanisms that regulate homing of myeloid precursors in the bone marrow, and the precursors enter the peripheral circulation and migrate to the site of primary tumor as well as to future sites of metastases (Figure 4). At the site of primary tumor, the MDSC are activated and in addition to immune suppressive factors and chemokines, expression of matrix metalloproteinases (MMPs) [138] and of VEGFR1 [140, 144] is induced. For example, in the murine Lewis Lung cancer model and a spontaneous breast cancer model, Gr-1⁺CD11b⁺ MDSC directly participated in tumor angiogenesis by liberating VEGF from tumor stroma via MMP9 [145]. In addition, a subpopulation of Gr-1⁺CD11b⁺CD31⁺ MDSC was found to directly participate in tumor neoangiogenesis [138]. In the tumor environment some MDSC differentiate into endothelial cells that further support the generation of new vasculature [138]. It has therefore been proposed that MDSC represent the angiogenic switch that allows tumors to expand beyond their natural boundaries.
Of note is the observation that recruitment of MDSC to primary tumor may also protect tumors from therapy. In animal tumor models, compensatory events have been observed between macrophages and neutrophils [146]; MDSC may increase the tumor's refractoriness to anti-VEGF antibody therapy, and MDSC infiltrate tumors after chemo – and radiation therapy and up-regulate pro-angiogenic factors such as VEGF [147].

Selected bone-marrow-derived MDSC also migrate to distant organs where they prepare what is known as the “pre-metastatic niche” (Figure 4) [140-142]. The pre-metastatic niche is characterized by clusters of myeloid cells that express VEGFR-1 and VLA-4 (integrin α4β1). They also express matrix metalloprotease-9 (MMP9). Tumor-derived growth factors induce fibronectin (the ligand for VLA-4) in resident fibroblasts and lysyl oxidase that modifies the extracellular matrix. This allows the infiltrating myeloid cells to interact with local cell types in the residing tissue, and provide a specialized area producing chemokines, growth factors, MMPs and adhesion molecules. Together the formation of these clusters prepares the site for arrival of tumor cells so that they can home to the site and develop into metastases [140, 141]. MDSC in pre-metastatic niches are also highly suppressive of T cell activation and function [142]. Elegant studies by Kaplan et al [140] demonstrated that the primary tumor determines where metastases are formed, primarily by regulating the induction of fibronectin expression in distant sites. For example, mice inoculated intradermally with Lewis Lung carcinoma developed metastasis restricted to the lung and liver whereas mice with implanted B16 melanoma developed widespread metastasis. However, mice treated with melanoma-derived conditioned medium before inoculation with Lewis Lung carcinoma developed widespread metastases resembling the B16 melanoma. The redirection of Lewis Lung metastases to non-conventional sites for this tumor was associated with high levels of VEGF and placental growth factor. Further analysis of the pre-metastatic lung tissue revealed that expression of the inflammatory proteins S100A8 and S100A9 was dramatically up-regulated by VEGF-A, TGFB, and TNFα released by the primary tumor [148, 149]. The up-regulation of the S100 molecules was unique to the lung, the site of later metastasis, and not found in other organs. S100A8 and A9 are potent chemoattractants to CD11b⁺ myeloid cells and induce myeloid cell activation [150-152]. S100A9 also inhibits differentiation of MDSC into dendritic cells and macrophages. However, S100-A8 and A9 also mediated chemoattraction of tumor cells acting through Toll-like receptor 4 on tumor cells [148, 153].

At other sites of metastases chemokines different from S100-A8 and A9 might play an important role in recruitment and activation of MDSC and tumor cells (Figure 4). For example, production of keratinocyte-derived chemoattractant by abdominal tumors was essential for the recruitment and expansion of a distinct population of metastasis-enabling MDSC in the liver [142]. Likewise, the chemokine/chemokine receptor pair CXCL12/CXCR4 is not only essential for migration of myeloid progenitor cells, but has also been implicated in migration of tumor cells, such as pancreatic, lung, breast, and prostate cancers [154-157]. In addition to regulating cell trafficking, signaling through CXCR4 also increases expression of cell surface integrin molecules and induces secretion of MMPs and angiogenic factors such as VEGF [155, 157].

**MDSC recruitment, activation, and expansion in tumor-bearing hosts**

There is ample evidence to suggest that recruitment of MDSC from the bone marrow to tumor and their activation is mediated mostly by chemokines [157, 158] and cytokines that are typical of inflammation [64, 97, 159-162]. Interestingly, investigators recently identified tumor-induced complement 5a as an activator of MDSC [163]. Those factors that control expansion of MDSC, i.e. myelopoiesis, are mostly tumor-derived whereas factors involved in activation of MDSC are mostly produced by stromal cells and activated T cells. Tumor-derived GM-CSF [89], G-CSF, IL-3, and VEGF have all been associated with accumulation...
and expansion of MDSC [143, 144, 164]. Likewise, IL-1β, IL-6, M-CSF, SCF, VEGF, prostaglandins, and COX-2 are all tumor-derived factors that can expand MDSC; inhibit their differentiation[165], and increase their resistance to apoptosis[166]. The importance of these cytokines on MDSC is supported by in vitro studies in which various combinations of these cytokines induced functionally active MDSC from normal peripheral blood mononuclear cells[167] Tumors capable of secreting these factors are more invasive and progress more rapidly, as was demonstrated in a mouse model using IL-1β-secreting and non-IL-1β-secreting tumors [168, 169]. Key in the signaling pathways triggered by these factors is the transcription factor STAT-3 that when activated promotes expansion and survival of myeloid progenitor cells [152, 170]. STAT-3 also induces accumulation of MDSC through expression of the chemoattractants S100-A8 and –A9 in MDSC, the receptors for which are also expressed on MDSC [151, 152]. Thus, the pro-inflammatory action of S100-A8/A9 involves autocrine and paracrine mechanisms [171]. Another important signaling pathway in MDSC activation is MyD88, a central adapter protein involved in signaling through most TLRs. Mice deficient in MyD88 do not develop increased levels of MDSC in response to sepsis [62].

On the other hand, T cell- and stroma-derived factors such as IFNγ [172], IL-4, IL-10, IL-13, and TGFβ induce activation of MDSC [173], meaning that they activate functional activity of MDSC as described earlier. Signaling of these molecules is mediated through STAT1, STAT6, and nuclear factor –κB. For example, IFNγ signals through STAT1 in MDSC which results in up-regulation of arginase 1 and iNOS [65]. It is interesting to note that IFNγ responsible for activating MDSC was found to be produced by activated tumor-infiltrating T cells with antitumor activity. As such, an antitumor immune response induces its own down-regulation through induction of MDSC. IFNγ can also induce expression of IDO in tumor-infiltrating dendritic cells and macrophages, and thereby induce T cell suppression [45]. IL-4 and IL-13 induce activation of STAT6 through binding to IL-4Rα in a subset of MDSC [65] which leads to expression of arginase 1 and production of TGFβ by MDSC.

The activation of MDSC also promotes crosstalk between MDSC and macrophages, and vice versa. Activation of CD14+ MDSC by pro-inflammatory cytokines such as IL1β leads to up-regulation of IL-10 production in MDSC that, in turn, down-regulates production of IL-12 in macrophages [107, 159].

**TARGETING MDSC**

The accumulation of MDSC is closely related to the extent of disease, and successful treatment of the inciting cancer with surgery or chemotherapy results in the regression of MDSC number [47].

In an interesting recent paper using an elegant model, Zhang et al [174] have shown that tumor growth is arrested by a single transfer of effector T cells that selectively target CD11b*Gr1+ MDSC that cross present antigens captured from surrounding cancer cells. Elimination of these tumor-associated MDSC resulted in tumor regression and sustained inhibition of tumor growth. The depletion of MDSC in murine models has been associated with an improved host immune response resulting in delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. Elimination of MDSC has been shown to restore CTL and NK function, and decrease tumor angiogenesis [138, 145, 174].

A large number of different strategies have been employed to deplete and/or inhibit MDSC [175, 176]. Additionally, regimens have been tested that modulate MDSC suppressor function [177] or induce differentiation of MDSC into mature macrophages, granulocytes,
and dendritic cells. An overview of the various MDSC targeting strategies is presented in Table 2; we will discuss a few of the strategies tested in humans in more detail.

One strategy attempts to promote differentiation of MDSC into macrophages, dendritic cells or granulocytes using all-trans retinoic acid (ATRA) [88]. ATRA is a metabolite of vitamin A and is clinically used for induction therapy of patients with acute promyelocytic leukemia [188, 189]. ATRA has been found to induce differentiation of normal immature myeloid cells into monocytes, macrophages, and dendritic cells. Using MDSC (CD33+DR−) from patients with metastatic renal cell carcinoma in vitro, ATRA was found to restore cytolytic T cell activity, and together with GM-CSF induced differentiation of MDSC into antigen-presenting cell precursors [100]. Tested in patients with renal cell carcinoma, ATRA induced a substantial decrease in MDSC in the periphery and improved antigen-specific T cell responses [178]. Likewise, vitamin D3 can reduce the number of MDSC by inducing differentiation, and has shown promise in patients with head and neck cancer [179]. Lastly, GM-CSF-producing tumor vaccines have been used in an attempt to induce differentiation of MDSC in the tumor environment. However, there appears to be a threshold concentration in the circulation above which GM-CSF impairs antitumor activity through induction of MDSC [162, 190].

Alternative strategies focus on blocking the expansion of MDSC. For example, blockade of stem-cell factor function decreased MDSC expansion and tumor angiogenesis [181]. Targeting of VEGF using a specific antibody, bevacizumab (Avastin®), reduced the prevalence of CD11b+VEGFR1+ cells in the periphery [100]. However, a fusion protein known as VEGF-trap that binds all forms of VEGF and placental growth factor administered to patients with refractory solid tumors did not have any effect on MDSC prevalence although it did increase the proportion of mature dendritic cells [182]. Likewise, anti-VEGF antibody, bevacizumab treatment of patients with advanced metastatic renal cell carcinoma did not alter the prevalence of MDSC in the peripheral blood [58]. Another strategy aims to block signaling through VEGFR. The tyrosine kinase inhibitor, sunitinib for example blocks signaling through VEGFR, platelet-derived growth factor receptor, stem cell factor receptor (c-kit) and CSF-1R [191]. Sunitinib is being used in patients with clear cell renal cell carcinoma in which genetically-induced overproduction of VEGF has been associated with the pathogenesis of the disease. Treatment of patients with metastatic RCC significantly reduced the prevalence of CD33+DR− and CD15+CD14− MDSC subsets [99]. The reduction in MDSC was associated with a reduction in Treg and an increase in effector T cell populations in peripheral blood of patients. It should be noted that VEGF signaling pathways have been targeted also because of their role in promoting angiogenesis. While the therapies had a demonstrable inhibitory effect on tumor angiogenesis, the effect was transitory, most likely due to resistance to therapy [147].

Targeting effector mechanisms of MDSC has also shown promise such as by administration of cyclooxygenase 2 (COX-2) inhibitors in patients with renal cell carcinoma. COX-2 is required for production of prostaglandin E2 which is essential for the up-regulation of arginase 1 in MDSC. PGE-E2 also inhibits effector T cell activity; stimulates Treg, and activates IDO, the enzyme that converts tryptophan, an essential amino acid for survival of effector T cells. In an animal model of spontaneous pancreatic cancer, COX-2 inhibitors significantly improved the antitumor immune response in combination with low-dose gemcitabine and vaccine [185]. Inhibition of phosphodiesterase-5 using sildenafil (Viagra) leads to an IL-4Rα-mediated decrease in arginase 1 and NOS-2 expression in MDSC, and restored T cell proliferation in vitro [192] and in vivo [193]. In a recent study, bardoxolone methyl (CDDO-Me) was tested in patients with pancreatic cancer together with gemcitabine in an attempt to block the production of reactive oxygen species from MDSC. CDDO-Me completely blocked MDSC-mediated suppression of T cell proliferation in vitro and
significantly improved patients’ T cell responses to tetanus toxoid and phytohemagglutinin but did not alter the prevalence of MDSC [183].

Finally, certain chemotherapeutic drugs such as gemcitabine may be capable of directly eliminating MDSC. Gemcitabine has been shown in mouse tumor models to preferentially deplete MDSC through an unknown mechanism while leaving other immune cells intact [16, 17, 187]. Other pharmaceutical agents have been observed to target MDSC as well. Zoledronic acid, a potent aminobisphosphonate that inhibits farnesyl-pyrophosphate-transferase, has been shown to inhibit the tumor mediated increase in hematopoiesis which generates MDSC [145]. Although the mechanism of action in tumor bearing animals appears to involve modification of hematopoiesis, hematological toxicities of the drug on normal bone marrow are essentially not observed. Using pharmacological targeting of MDSC with zoledronic acid, improved anti-tumor effects have been observed including restoration of NK and CD8+ T cell activity [65] and decreased tumor angiogenesis [181]. The action of zoledronic acid on MDSC is of particular interest in pancreatic cancer as it appears that gemcitabine, the first-line agent and mainstay of treatment of this disease, also preferentially acts on MDSC. Thus, the combination of these two drugs is a potential method for overcoming the potent tumor-induced immunosuppression of pancreatic cancer.

The immunologic mechanism and anti-neoplastic effects of zoledronic acid

Aminobisphosphonates were originally developed as osteoclast inhibitors used to treat malignant and nonmalignant bone disease due to their high affinity for the bone matrix. Recent studies, however, have demonstrated impressive immunomodulatory, antitumor, and antimetastatic effects in patients with prostate and breast cancer [194]. Zoledronic acid is a third generation aminobisphosphonate and acts by inhibiting farnesyl-pyrophosphate synthase and prevention of downstream prenylation of various signaling proteins affecting multiple survival and trafficking pathways [195].

Zoledronic acid has been demonstrated to have direct antiproliferative, antimetastatic, and proapoptotic effects on human pancreatic cancer cell lines in vitro [196]. In addition, zoledronate has been shown to have positive immunomodulatory effects denoted by the up-regulation of the number and activity of gamma-delta-T cells [197], suppression of proangiogenic factors including VEGF and MMP-9, and the blockade of tumor-induced MDSC expansion [198-201].

The bone marrow is believed to serve as a reservoir of functional Treg [202], MDSC [145], and bone marrow derived cells which facilitate tumor growth and metastasis [140]. The CXCR4/CXCL12 chemotaxis pathway plays a critical role in maintaining homeostasis in the bone marrow among the various progenitor cells [155]. Disruption of this axis results in the efflux of myeloid precursors and immature myeloid cells which then can migrate to the primary tumor and sites of future metastasis and become MDSC (Figure 4) [140, 202, 203]. Zoledronic acid has been demonstrated to abrogate the effect of alterations in the CXCR4/ CXCL12 axis, and thereby prevent pre-MDSC from entering the bloodstream.

Recently, aminobisphosphonates have been shown to inhibit the accumulation of MDSC in the tumor environment in a breast cancer animal model by preventing tumor-induced myeloid hematopoiesis [145]. Just as in previous investigations, reduction of MDSC in tumors was associated with decreased levels of VEGF and MMP9, conferring a relative inability of tumors to induce neoangiogenesis [145]. Our group has observed that treatment with zoledronic acid significantly inhibits the accumulation of MDSC in mice inoculated subcutaneously with pancreatic cancer cells (Figure 5, Porembka et al., submitted). The decrease in MDSC at the site of tumor correlated with decreased tumor growth and improved survival in the murine model of pancreatic cancer. In addition, a decrease in the
number of Treg cells and mast cells was observed while the relative number of immune effectors cells increased (Porembka et al., submitted). Because of these findings, we hypothesize that the effect of zoledronic acid on MDSC may inhibit the immunosuppressive tumor microenvironment and potentially improve the efficacy of standard gemcitabine-based chemotherapy regimens.

Targeting MDSC and Treg in human pancreatic cancer

Important considerations in the design of clinical studies in pancreatic cancer are the late detection of the disease, and the high recurrence rate after surgical resection. More than 80% of patients present with inoperable disease. Of the remaining patients that are candidates for surgery, approximately 50% will develop recurrent disease within one year from the time of surgery. This suggests that at the time of surgery micrometastatic disease may be already present in a large number of patients. As discussed above, bone marrow-derived MDSC are instrumental in the formation of metastases and in development of primary tumors (Figure 4). As such, targeting of MDSC in pancreatic cancer patients should arguably be initiated at the time of detection. This consideration is also supported by recent data from mouse models in which pancreatic adenocarcinoma spontaneously develops [42, 109, 204, 205], and is exacerbated by introducing additional genetic alterations [205, 206]. One of these models [204, 206] is based on activation of the Ras oncogene in the pancreas, and resembles pancreatic cancer development in humans by both genetic and histologic criteria. In the second model, transforming growth factor α, expressed in the pancreas in p53 deficient mice also leads to spontaneous formation of pancreatic adenocarcinoma [205]. Interestingly, the development of pancreatic neoplasms, starting with dysplasia, is already associated with an increased prevalence of MDSC, Treg, and TAM with no or little evidence for an antitumor immune response in both models [109, 205]. These findings further support the notion that pancreatic cancers induce a strong immunosuppressive environment early on in the disease.

We have initiated a clinical trial in which patients with resectable pancreatic adenocarcinoma will be treated with peri-operative zoledronate plus standard adjuvant (gemcitabine) therapy. The two main objectives are to evaluate the safety and feasibility of perioperative neoadjuvant zoledronic acid, and to evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival. When combined with current adjuvant chemotherapy, the use of zoledronic acid in the neoadjuvant and adjuvant setting might result in a more robust antitumor immune response leading to increased overall survival through the prevention of local disease and distant metastasis.

SUMMARY

There is compelling evidence that cancers induce a highly immunosuppressive environment mainly through MDSC that suppress antitumor immunity and promote tumor growth and formation of metastases. While the scientific interest in MDSC has dramatically increased over the past several years, their characterization, in particular the phenotypic characterization is still incomplete. In part this may be because the tumor-induced blockade of lineage differentiation may not be uniform and/or may change over time. Additionally, evidence has emerged that at least two main subsets of MDSC exist consisting of inflammatory monocytes and granulocytes/neutrophils.

In spite of these gaps in our knowledge, several MDSC targeting strategies have been developed with encouraging results in animal tumor models. Most promising is that MDSC can be targeted at multiple levels, ranging from recruitment and activation to differentiation or elimination, suggesting combination strategies are possible and perhaps most effective. As new data become available that more clearly define the biology of MDSC and its subset composition, improved strategies can be designed.
Clinical translation of MDSC targeting strategies is still in its infancy but will be critical to move the field forward. In this context, we have opened a clinical trial using perioperative zoledronic acid in pancreatic adenocarcinoma that we hope will contribute insights into MDSC biology and focus attention on the bone marrow as a key target to prevent tumor progression.

Acknowledgments
Supported in part by NIH T32 CA09621 (JBM, MRP, MCBT)

Abbreviations used

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDSC</td>
<td>myeloid-derived suppressor cell</td>
</tr>
<tr>
<td>Treg</td>
<td>T regulatory cell</td>
</tr>
<tr>
<td>CTL</td>
<td>cytotoxic T lymphocyte</td>
</tr>
<tr>
<td>Th</td>
<td>T helper</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>MHC</td>
<td>major histocompatibility complex</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed cell death ligand-1</td>
</tr>
<tr>
<td>TGFβ</td>
<td>transforming growth factor beta</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>IDO</td>
<td>indoleamine 2,3-dioxygenase</td>
</tr>
<tr>
<td>TAM</td>
<td>tumor-associated macrophage</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer</td>
</tr>
<tr>
<td>iNOS</td>
<td>inducible nitric oxide synthase</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>cytotoxic T lymphocyte-associated antigen-4</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
<tr>
<td>M-CSF</td>
<td>macrophage-colony-stimulating factor, aka CSF-1</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte/macrophage-colony-stimulating factor, aka CSF-2</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor, aka CSF-3</td>
</tr>
<tr>
<td>MMP</td>
<td>matrix metalloproteinase</td>
</tr>
<tr>
<td>VLA</td>
<td>very late antigen</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>SCF</td>
<td>stem cell factor, aka Kit ligand (KITLG)</td>
</tr>
<tr>
<td>COX</td>
<td>cyclooxygenase</td>
</tr>
<tr>
<td>STAT</td>
<td>signal transducer and activator of transcription</td>
</tr>
<tr>
<td>TLR</td>
<td>toll-like receptor</td>
</tr>
<tr>
<td>ATRA</td>
<td>all-trans retinoic acid</td>
</tr>
<tr>
<td>PGE2</td>
<td>prostaglandin E2</td>
</tr>
</tbody>
</table>
References


47. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor


Figure 1.
Schematic representation of the balance between tumor growth and immune correlates.
Figure 2.
Hierarchical development of mature peripheral blood cells and MDSC through differentiation of hematopoietic stem cells (HSC) in mice. Differentiation of HSC is considered normal until the Granulocyte/Monocyte Precursor (GMP) stage. GMPs fail to differentiate into mature PMN and monocytes in a tumor-bearing host. Instead, GMPs give rise to MDSC that bear markers of both PMN and monocytes, but do not express markers of fully-matured cells. Please note that this diagram is meant primarily to illustrate the origin and main phenotypic markers of MDSC rather than depict in great detail the various differentiation pathways.
Figure 3.
Both monocytic and granulocytic MDSC infiltrate human pancreatic adenocarcinoma. A: Immunohistochemistry demonstrates a high prevalence of CD15^+CD11b^+ MDSC in tissue samples resected from patients with pancreatic adenocarcinoma. Red (CD11b) and green (CD15) fluorescence is shown with co-localization of CD15^+CD11b^+ MDSC indicated by yellow. B: Co-localization of CD11b (blue) and CD14 (red) indicated by pink/purple, and CD11b and CD15 (green) indicated by aqua. Additionally, co-localization of CD14 and CD15 is noted in some cells (pink plus aqua).
Figure 4.
Schematic overview of the role of MDSC in promoting tumor development. Developing tumors secrete factors such as VEGF, chemokines and inflammatory cytokines that induce myelopoiesis in the bone marrow. These factors also cause an imbalance in homing mechanisms of myeloid precursors which in turn leads to release of myeloid precursors into the circulation. Chemokine receptor expression on these myeloid cells directs them to various locations in the host where the corresponding ligand is expressed. For example, MDSC recruitment to primary tumor promotes angiogenesis and immune suppression, whereas MDSC recruitment to distant organs, e.g. liver, promotes the formation of metastasis. Mechanisms for MDSC recruitment, e.g. CXCR4 are also exploited by metastatic tumor cells.
Figure 5.
Zoledronate treated mice have smaller pancreatic tumors compared with untreated tumor-bearing mice. C57BL/6 mice (n=5) were challenged with $1.0 \times 10^5$ viable Pan02 cells on day 0 (injected subcutaneously in the left thigh). Treatment with either placebo or zoledronate was initiated on day 10, when subcutaneous pancreatic tumors were present by palpation. Zoledronate at a dose of 0.1 mg/kg was diluted in saline and administered daily subcutaneously for 5 days per week. Control mice (n=5) received 0.2 mL of saline daily subcutaneously. Shown is the average tumor volume per group; error bars indicate the standard error of the mean (p<0.01).
Table 1

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Suppressor cell phenotype</th>
<th>Model</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ROS release</strong></td>
<td>CD11b, Ly6G&lt;sup&gt;+&lt;/sup&gt;Ly6C&lt;sup&gt;lo&lt;/sup&gt; CD11b, GR-1</td>
<td>7 different tumor models (mice) 10 different tumor models (mice) Advanced cancer (human) CT26 colon, C-3 sarcoma (mice)</td>
<td>[96] [57] [59] [123]</td>
</tr>
<tr>
<td></td>
<td>CD11b, Ly6G&lt;sup&gt;+&lt;/sup&gt;Ly6C&lt;sup&gt;lo&lt;/sup&gt; CD11b, CD15 CD11b,GR-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Peroxynitrite release</strong></td>
<td>CD11b, GR-1</td>
<td>EL4 (mice)</td>
<td>[124]</td>
</tr>
<tr>
<td></td>
<td>CD11b, CD15</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Arginase 1 release</strong></td>
<td>CD11b, GR-1</td>
<td>3LL (mice), NSCLC (human)</td>
<td>[126]</td>
</tr>
<tr>
<td></td>
<td>CD11b, CD66b</td>
<td>RCC (human)</td>
<td>[58]</td>
</tr>
<tr>
<td></td>
<td>CD11b,GR-1,Ly6C&lt;sup&gt;lo&lt;/sup&gt; CD11b,CD15</td>
<td>5 different tumor models (mice) RCC (human)</td>
<td>[65] [57]</td>
</tr>
<tr>
<td><strong>iNOS release</strong></td>
<td>CD11b, Ly6G&lt;sup&gt;+&lt;/sup&gt;Ly6C&lt;sup&gt;lo&lt;/sup&gt; CD11b,GR-1,Ly6C&lt;sup&gt;lo&lt;/sup&gt; CD11b,GR-1,Ly6C&lt;sup&gt;hi&lt;/sup&gt; CD11b,Ly6C&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>10 different models (mice) 5 different tumor models (mice) EAE (mice)</td>
<td>[87] [65] [127]</td>
</tr>
<tr>
<td><strong>TGFβ secretion</strong></td>
<td>GR-1, CD115</td>
<td>MCA-26 colon carcinoma (mice)</td>
<td>[93]</td>
</tr>
<tr>
<td><strong>IL-10 secretion</strong></td>
<td>CD11b, GR-1</td>
<td>4T1 breast carcinoma (mice)</td>
<td>[107]</td>
</tr>
<tr>
<td></td>
<td>GR-1, CD115</td>
<td>MCA-26 colon carcinoma (mice)</td>
<td>[93]</td>
</tr>
<tr>
<td><strong>Cysteine depletion</strong></td>
<td>CD11b, GR-1</td>
<td>4T1 breast carcinoma (mice)</td>
<td>[131]</td>
</tr>
<tr>
<td><strong>CD62L down-regulation</strong></td>
<td>CD11b, GR-1</td>
<td>4T1 breast carcinoma (mice)</td>
<td>[133]</td>
</tr>
<tr>
<td><strong>B7-H4, PD-L1 (B7-H1) expression</strong></td>
<td>CD68, CD1a,HLA-DR</td>
<td>HCC (human)</td>
<td>[136]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ovarian cancer (human)</td>
<td>[134, 135]</td>
</tr>
</tbody>
</table>

NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma; EAE is Experimental Autoimmune Encephalomyelitis; HCC, hepatocellular carcinoma
<table>
<thead>
<tr>
<th>Target</th>
<th>Reagent</th>
<th>Type of cancer</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Induction of MDSC differentiation</td>
<td>ATRA</td>
<td>Renal cell carcinoma, Head and neck cancer</td>
<td>[88, 100, 178]</td>
</tr>
<tr>
<td>Induction of MDSC differentiation</td>
<td>Vitamin D3</td>
<td>Head and neck cancer</td>
<td>[179]</td>
</tr>
<tr>
<td>Induction of MDSC differentiation</td>
<td>GM-CSF</td>
<td>Malignant melanoma</td>
<td>[180]</td>
</tr>
<tr>
<td>Blockade of MDSC expansion/activation</td>
<td>SCF</td>
<td>Colon carcinoma</td>
<td>[181]&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Blockade of MDSC function</td>
<td>Anti-VEGF Ab +/- IL-2</td>
<td>Renal cell carcinoma</td>
<td>[58]</td>
</tr>
<tr>
<td>Blockade of MDSC function</td>
<td>VEGF-trap</td>
<td>Advanced tumors</td>
<td>[182]</td>
</tr>
<tr>
<td>Blockade of MDSC function</td>
<td>Sunitinib</td>
<td>Renal cell carcinoma</td>
<td>[99]</td>
</tr>
<tr>
<td>Blockade of MDSC function</td>
<td>CDDO-Me&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Pancreatic cancer</td>
<td>[183]</td>
</tr>
<tr>
<td>Blockade of MDSC function</td>
<td>COX-2 inhibitors&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Intestinal tumors, Pancreatic cancer, Lung cancer</td>
<td>[184], [185], [186]</td>
</tr>
<tr>
<td>Elimination of MDSC</td>
<td>Gemcitabine</td>
<td>Lung cancer and Mesothelioma, Colon cancer</td>
<td>[16]&lt;sup&gt;b&lt;/sup&gt;, [187]&lt;sup&gt;b&lt;/sup&gt;, [17]&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Recruitment of MDSC</td>
<td>Aminobisphosphonates</td>
<td>Breast cancer, Pancreatic cancer&lt;sup&gt;c&lt;/sup&gt;</td>
<td>[145]&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>CDDO-Me is the triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid

<sup>b</sup> Mouse model

<sup>c</sup> Linehan et al., ongoing clinical study